Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) – an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System

- Designations reinforce unmet need for treatment options for patients, especially children with ATRT - LP-184 for the potential treatment of ATRT is the third program of Lantern to receive orphan drug designation

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here